ACORN BIOVENTURES, L.P. 13D and 13G filings for Cardiff Oncology, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-06 4:01 pm Sale |
2023-12-31 | 13G | Cardiff Oncology, Inc. CRDF |
ACORN BIOVENTURES, L.P. | 1,946,762 4.200% |
-1,096,411 (-36.03%) |
Filing |
| 2023-01-26 1:30 pm Unchanged |
2023-01-26 | 13G | Cardiff Oncology, Inc. CRDF |
ACORN BIOVENTURES, L.P. | 3,043,173 6.380% |
0 (Unchanged) |
Filing |
| 2023-01-26 1:28 pm Sale |
2022-09-13 | 13D | Cardiff Oncology, Inc. CRDF |
ACORN BIOVENTURES, L.P. | 3,043,173 6.380% |
-2,947,666 (-49.20%) |
Filing |
| 2020-07-02 2:59 pm Purchase |
2020-06-15 | 13D | Cardiff Oncology, Inc. CRDF |
ACORN BIOVENTURES, L.P. | 5,990,839 9.990% |
4,303,279 (+255.00%) |
Filing |
| 2020-06-04 4:14 pm Purchase |
2020-05-27 | 13G | Cardiff Oncology, Inc. CRDF |
ACORN BIOVENTURES, L.P. | 1,687,560 9.990% |
1,687,560 (New Position) |
Filing |